Skip to main content

Closed

SYRE: Spyre Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-100.0% / yr

Operating margin-222.8%

ROIC-29.7%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio8.97×

Spyre Therapeutics, Inc.

SYRENASDAQ Capital Market·USD·Closed

Spyre Therapeutics, Inc.

SYRENASDAQ·USD·Closed

$98.33

−3.12%

$98.33

−$3.17 (3.12%)

52W Range

93thpctl

Volume

0.43×avg

Mkt Cap

8.54BUSD

P/E

-45.1TTM

Div Yield

–ann

52W Range

93thpctl

Volume

0.43×avg

Market Cap

8.54BUSD

P/E Ratio

-45.1TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings